Cellebrite DI Ltd. Investigation
Company: Cellebrite DI Ltd.
Ticker: (NASDAQ) CLBT
How to Check Whether You May Be Eligible in the Cellebrite DI Ltd. Investigation
Investigation Details
Cellebrite DI Ltd. shareholders lost money in August 2026 when the stock fell sharply after the Company reported Q2 2026 financial results that missed revenue expectations, lowered full-year ARR and revenue guidance, and announced a CEO transition. Management conceded they "did not deliver the ARR and revenue performance they expected in the second quarter." Notably, the Company reported ARR of $507.8 million, below the $510-$513 million range provided last quarter. Q2 revenue of approximately $131.1 million also came in below analyst consensus. Despite previous claims in February, 2026, of being "well positioned to reaccelerate growth," Cellebrite ultimately slashed its projected ARR growth rate for fiscal 2026 to 14%-16%, down from the 18%-19% target reaffirmed just last quarter. Management pointed to a "meaningful acceleration" in Q2 that never manifested and several large transactions that were delayed. The investigation concerns whether Cellebrite DI Ltd. adequately disclosed the risks inherent in its prior projections ahead of its Q2 2026 earnings report.